article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 The post UK biotech sees worst funding downturn since 2012 appeared first on. billion, way down from £4.5 billion in 2021. billion raised.

article thumbnail

Cell and gene therapy market set to grow at 44% CAGR through 2030: GlobalData

Express Pharma

The global cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate of 44 per cent, with sales projected to rise from $8.70 billion in 2024 to $76.03 billion in 2030.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone. study in the Archives of Internal Medicine found that nearly 20% of older adults on new medications experienced a prescribing cascade (Archives of Internal Medicine, 2012). Campbell, N.

article thumbnail

Ethnopharmacology: traditional medicine and modern drug discovery

Pharmaceutical Technology

For example, a widely referenced study from 2012 reported that up to 50% of approved drugs between 1981 and 2010 were directly or indirectly from natural products, while according to the WHO, 11% of drugs considered basic or essential originated from flowering plants.

article thumbnail

Bayer adds menopause drug to pipeline with KaNDy acquisition

pharmaphorum

A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23. This high compound annual growth rate of 23.6%

Immunity 105
article thumbnail

Evaluating NMR relaxometry for antibody identification

European Pharmaceutical Review

NMR relaxation methods distinguish between components (phases or compounds) that have different molecular mobilities For monoclonal antibodies, identification methodologies can employ chromatography, spectroscopy, isoelectric focusing, capillary electrophoresis and peptide mapping techniques. 2012; 2012: 1–7. Chromatography.